Robert H. Vonderheide
Directs Penn's cancer centre and pioneered CD40 agonist immunotherapy for pancreatic cancer.
Physician-scientist whose lab showed CD40 activation can license macrophages and T cells against pancreatic tumours, leading to clinical trials of CD40 agonists with chemotherapy and PD-1 blockade.
| Title | Journal | Year |
|---|---|---|
| CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Science | 2011 |
Pages like this
not linked directly; found by shared links- PersonPeter J. O'Dwyer
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
- TechnologyEngineered bacteria as living cancer drugs
Shares Cytokines & engineered cytokines, Pancreatic ductal adenocarcinoma.
- TechnologyIntratumoural gene electrotransfer (IL-12 plasmid)
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.
- TechnologyTrained innate immunity
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.
- IdeaEngineered bacteria that live in tumours and manufacture drugs there
Shares Cytokines & engineered cytokines, Pancreatic ductal adenocarcinoma.
- IdeaGrow immune command posts inside tumours
Shares Cytokines & engineered cytokines, Immune checkpoint inhibitors.
- PersonSusan M. Domchek
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
- PathwayAutophagy
Shares Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.